




RealRate

PHARMACEUTICAL 2020

DYNAVAX TECHNOLOGIES CORP
Rank 206 of 362

DYNAVAX



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of DYNAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAX TECHNOLOGIES CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 44% points. The greatest weakness of DYNAX TECHNOLOGIES CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 50% points.

The company's Economic Capital Ratio, given in the ranking table, is -222%, being 81% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	208,653
Cost of Goods Sold	0
Intangible Assets	4,581
Liabilities, Current	53,047
Liabilities, Non-Current	217,731
Other Assets	33,812
Other Compr. Net Income	-372
Other Expenses	57,222
Other Liabilities	0
Other Net Income	4,101
Property and Equipment	32,022
Research and Development	62,331
Revenues	37,838
Selling, General and Administrative Expense	74,986

Output Variable	Value in 1000 USD
Assets	279,068
Liabilities	270,778
Expenses	194,539
Stockholders Equity	8,290
Net Income	-152,600
Comprehensive Net Income	-152,786
Economic Capital Ratio	-222%